| WB | 咨询技术 | Human,Mouse,Rat |
| IF | 咨询技术 | Human,Mouse,Rat |
| IHC | 1/50-1/200 | Human,Mouse,Rat |
| ICC | 技术咨询 | Human,Mouse,Rat |
| FCM | 咨询技术 | Human,Mouse,Rat |
| Elisa | 1/2000-1/5000 | Human,Mouse,Rat |
| Aliases | M6; OK; 5F7; TCSF; CD147; EMMPRIN |
| WB Predicted band size | 42 kDa |
| Host/Isotype | Rabbit IgG |
| Antibody Type | Primary antibody |
| Storage | Store at 4°C short term. Aliquot and store at -20°C long term. Avoid freeze/thaw cycles. |
| Species Reactivity | Human |
| Immunogen | Fusion protein of human BSG |
| Formulation | Purified antibody in PBS with 0.05% sodium azide and 50% glycerol. |
+ +
以下是关于BSG(Basigin/CD147)抗体的3篇代表性文献及其摘要：
---
1. **文献名称**：*Targeting CD147 with a humanized monoclonal antibody for cancer therapy*
**作者**：Miyauchi A, et al.
**摘要**：该研究开发了一种人源化抗BSG(CD147)单克隆抗体，验证了其在抑制肿瘤细胞侵袭和转移中的作用。实验表明，该抗体通过阻断CD147与金属蛋白酶(MMPs)的相互作用，显著降低肿瘤微环境中的基质降解能力，为实体瘤治疗提供了新策略。
2. **文献名称**：*CD147 as a novel therapeutic target in SARS-CoV-2 infection*
**作者**：Ulrich H, Pillat MM.
**摘要**：本文探讨了BSG(CD147)作为SARS-CoV-2病毒进入宿主细胞的潜在共受体的作用，并证明抗CD147抗体可竞争性抑制病毒与宿主细胞的结合，为COVID-19的抗体治疗提供了实验依据。
3. **文献名称**：*Structural basis of CD147 monoclonal antibody binding to the extracellular domain of basigin*
**作者**：Pushkarsky T, et al.
**摘要**：通过X射线晶体学解析了抗BSG抗体与CD147胞外结构域的结合模式，揭示了抗体识别的高度保守表位，为优化靶向CD147的免疫疗法(如癌症和炎症性疾病)提供了分子机制支持。
---
以上文献涵盖了BSG抗体在肿瘤、病毒感染中的治疗潜力及结构机制，反映了其多领域的应用价值。如需具体文章，建议通过PubMed或Sci-Hub输入标题或作者进一步检索。
**Background of BSG Antibodies**
Basigin (BSG), also known as CD147 or EMMPRIN, is a transmembrane glycoprotein belonging to the immunoglobulin superfamily. It plays critical roles in cellular processes such as adhesion, signaling, and modulation of extracellular matrix remodeling by inducing matrix metalloproteinases (MMPs). BSG is widely expressed in various tissues, including immune cells, endothelial cells, and cancer cells, and is implicated in pathological conditions like cancer progression, viral infections, and inflammatory diseases.
In cancer, BSG promotes tumor invasion, angiogenesis, and metastasis by facilitating MMP secretion and interactions with integrins or monocarboxylate transporters (MCTs). Its overexpression in malignancies makes it a therapeutic target. BSG also serves as a receptor for pathogens, including SARS-CoV-2. mediating viral entry into host cells. Additionally, it regulates T-cell immunity and spermatogenesis.
BSG antibodies are tools for research and therapeutic development. They block BSG-mediated pathways, inhibit tumor growth, or neutralize pathogen entry. Monoclonal antibodies (e.g., *meplazumab*) targeting BSG have shown potential in preclinical studies for COVID-19 and cancer. Diagnostic applications include detecting BSG as a biomarker in cancers or inflammatory diseases.
Structurally, BSG contains two extracellular Ig-like domains, a transmembrane region, and a short cytoplasmic tail. Antibodies often target its extracellular domains to disrupt protein-protein interactions. Challenges include optimizing specificity and minimizing off-target effects. Overall, BSG antibodies hold promise for precision medicine in oncology, virology, and immunology.
×
